Fosun Pharmaceutical (02196): F-SR031 injection approved for clinical trials

Zhitongcaijing · 6d ago

Zhitong Finance App News, Fosun Pharmaceutical (02196) announced that recently, Chengdu Xingrui Jingxuan Biotechnology Co., Ltd., the holding subsidiary of the company, received clinical trial approval from the State Drug Administration to approve [18F] F-SR031 injection for positron emission tomography (PET) imaging of fibroblast-activating protein (FAP) positive lesions in patients with solid tumors. Xingrui Jingxuan plans to conduct phase I clinical research on this drug in China when conditions are met.